Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Relief Therapeutics Holding AG    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/22/2021 02/23/2021 02/24/2021 02/25/2021 02/26/2021 Date
0.33(c) 0.309(c) 0.36(c) 0.32(c) 0.318(c) Last
15 372 595 15 932 929 55 425 261 20 086 490 18 545 495 Volume
+0.61% -6.36% +16.50% -11.11% -0.63% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Sales 2021 304 M 334 M 334 M
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 1 032 M 1 137 M 1 135 M
Capi. / Sales 2020 -
Capi. / Sales 2021 3,40x
Nbr of Employees 10
Free-Float 49,7%
More Financials
Company
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either... 
More about the company
All news about RELIEF THERAPEUTICS HOLDING AG
02/24RELIEF THERAPEUTICS : Partner NeuroRx Sees Positive Results of Aviptadil in COVI..
MT
02/24RELIEF REPORTS : NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Acc..
PU
02/24RELIEF REPORTS : NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Acc..
EQ
02/23NeuroRx Says Trial Shows Positive Results at Day 28 in Critically Ill Patient..
MT
02/23NEURORX : Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrate..
PR
02/10RELIEF THERAPEUTICS : RLF-100 Therapy Found to Lower Hospitalization in COVID-19..
MT
02/10RELIEF THERAPEUTICS : Confirms Release of Preliminary Findings from Phase 2b/3 T..
PU
02/10RELIEF THERAPEUTICS : Confirms Release of Preliminary Findings from Phase 2b/3 T..
EQ
02/09NEURORX : and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demons..
PR
02/09RELIEF THERAPEUTICS : Announces Resignation of Thomaz Burckhardt as Member of th..
PU
02/09RELIEF THERAPEUTICS : Announces Resignation of Thomaz Burckhardt as Member of th..
EQ
02/08RELIEF THERAPEUTICS : Partner NeuroRx Begins Phase 2/3 Trial for RLF-100 in Crit..
MT
02/08RELIEF THERAPEUTICS : Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100&t..
PU
02/08EQS-NEWS : Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (..
DJ
01/25RELIEF THERAPEUTICS : and Acer Therapeutics Sign Option Agreement for Exclusivit..
PU
More news
News in other languages on RELIEF THERAPEUTICS HOLDING AG
02/24Aktien Schweiz Schluss: SMI gewinnt über ein Prozent
02/24Bourse Zurich: les indices ont effacé une partie des pertes du début de semai..
02/24Aktien Schweiz: SMI erobert in Gegenbewegung 10'700er Marke zurück
02/24Bourse Zurich: les indices compensent en matinée les pertes de la veille
02/24Bourse Zurich: regain de confiance généralisé en début de séance
More news
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 0,78 CHF
Last Close Price 0,32 CHF
Spread / Highest target 144%
Spread / Average Target 144%
Spread / Lowest Target 144%
Managers and Directors
NameTitle
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Gilles Della Corte Chief Medical Officer
Jeremy Meinen Vice President-Finance & Administration
Peter Egon de Svastich Director
Sector and Competitors
1st jan.Capitalization (M$)
RELIEF THERAPEUTICS HOLDING AG18.22%1 137
MODERNA, INC.48.19%61 888
LONZA GROUP AG0.88%46 924
IQVIA HOLDINGS INC.7.60%36 971
CELLTRION, INC.-17.13%35 993
SEAGEN INC.-13.72%27 376